Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Valrox

    - PMLiVE

    Novo Nordisk agrees to lower certain drug prices in the US

    The company's semaglutide-based weight-loss drugs will be made available in the US through Medicare and Medicaid

    - PMLiVE

    Lilly announces agreement with US government to lower patient costs

    The agreement will make insulin and obesity treatments more affordable through federal programmes and direct-to-patient channels

    - PMLiVE

    Sobi receives NICE recommendation for Altuvoct in severe haemophilia A

    Approximately 7,700 people in England are living with the genetic bleeding disorder

    - PMLiVE

    Sobi receives MHRA approval for Altuvoct in severe or moderate haemophilia A

    The factor VIII replacement therapy has been authorised to treat and prevent bleeding in children and adults

    - PMLiVE

    Novo Nordisk’s haemophilia A therapy Mim8 shows promise in late-stage study

    The inherited bleeding disorder accounts for up to 85% of the 1,125,000 global haemophilia cases

    - PMLiVE

    What is willingness to pay? – Comparing price testing methodologies

    Heather Wellam (Senior Consultant – Market Access, Mtech Access) explores the concept of willingness to pay (WTP) and what it means for pharmaceutical and medtech pricing strategy. Read on to...

    Petauri Evidence

    - PMLiVE

    Pfizer shares positive late-stage results for haemophilia A gene therapy

    The rare bleeding disorder occurs in approximately 25 in every 100,000 male births globally

    - PMLiVE

    Sanofi/Sobi’s haemophilia A therapy shows ‘highly effective’ bleed protection in children

    The rare bleeding disorder affects approximately one in every 5,000 male births annually

    - PMLiVE

    Novo Nordisk shares positive results for Mim8 in late-stage haemophilia A trial

    The inherited bleeding disorder accounts for up to 85% of the 1,125,000 global haemophilia cases

    - PMLiVE

    Sobi receives EC marketing authorisation for Altuvoct in haemophilia A

    The rare bleeding disorder affects approximately one in every 5,000 male births annually

    - PMLiVE

    Sanofi and Sobi’s Altuviiio label updated by FDA with expanded paediatric data in haemophilia A

    The therapy’s weekly dosing has a half-life of up to four times longer than current factor VIII therapies

    - PMLiVE

    Novo Nordisk’s haemophilia A therapy Mim8 shows promise in late-stage study

    Haemophilia A accounts for up to 85% of the 1,125,000 global haemophilia cases

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links